The Conversation (0)
ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
Feb. 28, 2018 09:36AM PST
Pharmaceutical InvestingProQR Therapeutics (Nasdaq:PRQR), announced results for the fourth quarter and full year 2017 and provided a business update. As quoted in the press release: “In the past year we made solid progress on our mission to create meaningful medicines for patients in need. I am proud of the milestones our team has achieved on all …
ProQR Therapeutics (Nasdaq:PRQR), announced results for the fourth quarter and full year 2017 and provided a business update.
As quoted in the press release:
“In the past year we made solid progress on our mission to create meaningful medicines for patients in need. I am proud of the milestones our team has achieved on all fronts – advancing our pipeline of ophthalmology programs, with QR-110 now in the clinic, positive proof-of-concept for eluforsen for CF, getting QR-313 ready for clinical trials and validating our novel RNA-editing technology, Axiomer®,” said Daniel A. de Boer, CEO of ProQR.
